Novartis Says Kisqali Significantly Lowered the Risk of Cancer Recurrence
By Giulia Petroni Novartis said that primary endpoint data from a Phase 3 trial showed that ribociclib drug treatment Kisqali significantly reduced the risk of cancer recurrence across a... | June 2, 2023